On this page
Turkey built a medical travel industry on hair transplants and dentistry and has extended it into regenerative medicine; Thailand built one on cardiac surgery and orthopaedics and has done the same. Thailand and Turkey are genuine alternatives for a European patient — and the comparison that matters is between clinics, not between countries.
What is actually being compared
Not the evidence. A trial conducted anywhere reports the same result regardless of which country you fly to for the intervention, and no destination improves a treatment’s underlying data.
What differs is access, cost, oversight, travel and what happens if something goes wrong afterwards.
Any page implying that one country’s treatments work better is comparing marketing rather than medicine — see what the evidence levels mean.
Distance, which decides more than people expect
For a European patient this is the largest practical difference. Istanbul is three to four hours from most of Western Europe; Bangkok is ten to twelve.
That changes everything about the logistics. A short flight makes a second visit feasible, which matters enormously for autologous treatment requiring a harvest then weeks of culture — see autologous therapy.
It also changes what happens if a complication appears a fortnight later. A three-hour flight back is an inconvenience; a twelve-hour one is a decision.
For Australian, Middle Eastern and Asian patients the calculation reverses, and Bangkok is the shorter journey — sometimes by a considerable margin.
The medical travel sectors are differently shaped
Turkey’s grew around high-volume cosmetic procedures — hair restoration, dentistry, aesthetic surgery — with an emphasis on package pricing and throughput.
Thailand’s grew around complex hospital medicine: cardiac surgery, orthopaedics, oncology. The infrastructure that produced is hospital-centred, with internationally accredited private institutions accustomed to foreign patients with serious conditions.
Neither history is a verdict on cell therapy specifically. It does shape what surrounds a clinic — and for anything carrying a risk of complications, proximity to a well-equipped private hospital is a real consideration.
It also shapes the commercial culture. A sector built on high-volume elective procedures tends toward packages, fixed prices and throughput; one built on complex hospital medicine tends toward assessment and itemisation. Neither is inherently better, and they suit different patients.
Regulation
Turkey regulates advanced therapy products through its health ministry, with a framework that has tightened in recent years as the medical travel sector has grown.
Thailand regulates through the Thai FDA and Ministry of Public Health — see regulation in Thailand.
Both are middle-ground jurisdictions: more permissive than the United States or the European Union for these specific products, not absent. In both, national reputation tells you far less than whether this facility is licensed and this practitioner registered.
Those two things are checkable from home in either country, and checking them is worth more than any amount of reading about national frameworks.
Cost
Broadly comparable, with variation inside each country much larger than the difference between them.
Turkey’s package pricing culture makes headline comparison easier and can obscure what is included. Thailand’s pricing is more often itemised, which is less convenient and more informative.
Either way the questions are the same: how many cells, from what source, how many treatments, what testing, what follow-up — see the cost page.
For Europeans, Turkey’s shorter flights reduce total trip cost meaningfully, particularly where two visits are needed. Two return flights to Istanbul and two to Bangkok are a different proposition entirely, and that difference belongs in the comparison rather than the headline treatment price.
Language and communication
Both countries have well-developed English-language medical services for international patients, and in both the quality varies by provider rather than by country. Turkey has the advantage of a large German- and Arabic-speaking patient base and staff to match; Thailand’s international sector serves a wider spread of nationalities.
What matters is whether the clinician assessing you speaks to you directly, or whether everything passes through a coordinator. A conversation with the person making the clinical decision is worth insisting on.
Ask, at either destination, whether you will speak to the doctor before you travel or only on arrival.
A coordinator relaying answers is not the same as a clinician answering. Both countries have clinics where the first clinical conversation happens after the deposit has been paid, and that ordering is worth noticing.
The question neither market answers well
Follow-up. Both sectors are organised around patients who arrive, are treated and leave, and neither has solved what happens in the months afterwards.
Ask both what follow-up is provided, whether anyone will correspond with your own physician, and what happens if the treatment does nothing.
The answers are usually thinner than the treatment descriptions, and that asymmetry is itself informative — see international patients.
How to actually decide
Send the same records to a clinic in each and compare the two assessments. That is the single most useful thing you can do, and it costs nothing.
You are looking for whether each engages with your specific imaging and history, whether either says no, and whether the proposals differ in cell type, dose or number of treatments — and if so, why.
A clinic that reads your records and declines is telling you something a clinic that offers treatment to everyone cannot — see the patient journey and the research library.
Do the same with the questions. Ask both for cell type, source, dose, release testing and follow-up in writing, and compare the answers rather than the brochures. Precision is the variable that separates providers, and it does not correlate with which country they are in.
Frequently asked questions
Which country is better for stem cell treatment?
Neither, on the evidence — that is identical wherever you fly. Turkey is closer for Europeans and Thailand has the more hospital-centred medical travel infrastructure, so the answer depends on where you start from.
Is Turkey cheaper?
Broadly comparable, though shorter flights reduce total trip cost for Europeans. Variation within each country is larger than between them.
Which is better regulated?
Both are middle-ground jurisdictions — more permissive than the US or EU, not unregulated. Check the specific facility and practitioner rather than the country.
Does distance matter?
More than people expect. It decides whether a second visit is feasible, which matters for autologous treatment, and what happens if a complication appears later.
Why does package pricing matter?
It makes comparison look easier while obscuring what is included. Itemised pricing is less convenient and tells you more.
What is the best way to choose?
Send the same records to one clinic in each and compare the assessments. It costs nothing and reveals more than any country comparison.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.